DRUG
Insulin glargine/lixisenatide fixed ratio combination
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Status
Completed
Phase
Phase 3
Enrollment
514
Locations
124
Results
Posted
Publications
5
Study summary
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change. Secondary Objectives: To compare the overall efficacy and safety of the insulin glargine/lixisenatide FRC to GLP-1 RA on top of metformin (with or without pioglitazone, with or without sodium-glucose co-transporter 2 \[SGLT2\] inhibitor) in participants with type 2 diabetes. To evaluate safety, efficacy and other endpoints of FRC up to the end of the extension period.
The maximum duration for GLP1-RA participants was approximately 29 weeks: up to 2 week screening period, a 26 week treatment period (either randomized or uncontrolled), and a 3 or 9 day post-treatment safety follow-up period. Maximum duration for FRC participants was approximately 55 weeks: up to 2-week screening period, a 26-week randomized treatment period, a 26-week extension period and a 3-day post-treatment safety follow-up period. All primary and secondary efficacy, safety and other outcome measures were assessed at the end of the extension period.
Interventions
DRUG
Pharmaceutical form: solution for injection Route of administration: subcutaneous
DRUG
Pharmaceutical form: solution for injection Route of administration: subcutaneous
DRUG
Pharmaceutical form: solution for injection Route of administration: subcutaneous
DRUG
Pharmaceutical form: solution for injection Route of administration: subcutaneous
DRUG
Pharmaceutical form: solution for injection Route of administration: subcutaneous
DRUG
Pharmaceutical form: solution for injection Route of administration: subcutaneous
DRUG
Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
Timeline
First posted
Jun 1, 2016
Study start
Jul 6, 2016
Primary completion
May 25, 2018
Study completion
Nov 17, 2018
Results posted
Jun 12, 2019
Registry updated
Mar 25, 2022
Outcomes
Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period
Time frame · Baseline, Week 26
Change in HbA1c was calculated by subtracting baseline value from Week 26 value. Adjusted least squares (LS) mean and standard error (SE) were obtained from Mixed-effect model with repeated measures (MMRM) to account for missing data using all available post baseline data during the 26 week treatment period.
Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 52: Single Arm Extension Period
Time frame · Baseline, Week 52
Change in HbA1c was calculated by subtracting baseline value from Week 52 value.
Percentage of Participants Reaching HbA1c <7% or <=6.5% at Week 26: Core Period
Time frame · Week 26
Participants without any available HbA1c assessment at Week 26 were considered as non-responders.
Percentage of Participants Reaching HbA1c <7 % or <=6.5% at Week 52: Single Arm Extension Period
Time frame · Week 52
Participants without any available HbA1c assessment at Week 52 were considered as non-responders.
Change From Baseline in Fasting Plasma Glucose (FPG) to Week 26: Core Period
Time frame · Baseline, Week 26
Change in FPG was calculated by subtracting baseline value from Week 26 value. Adjusted LS means and SE were obtained from MMRM to account for missing data using all available post baseline data during the 26 week treatment period.
Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52: Single Arm Extension Period
Time frame · Baseline, Week 52
Change in FPG was calculated by subtracting baseline value from Week 52 value.
Change From Baseline in the Daily Average of the 7-point Self-monitored Plasma Glucose (SMPG) to Week 26: Core Period
Time frame · Baseline, Week 26
The 7-point SMPG profile was measured at the following 7 points: pre-prandial and 2 hours postprandial for breakfast, lunch, dinner and at bedtime. Two hours postprandial (breakfast, lunch and dinner) was defined as 2 hours after the start of the meal. Adjusted LS means and SE were obtained from MMRM to account for missing data using all available post baseline data during the 26 week treatment period.
Change From Baseline in the Daily Average of the 7-point Self-monitored Plasma Glucose (SMPG) to Week 52: Single Arm Extension Period
Time frame · Baseline, Week 52
The 7-point SMPG profile was measured at the following 7 points: pre-prandial and 2 hours postprandial for breakfast, lunch, dinner and at bedtime. Two hours postprandial (breakfast, lunch and dinner) was defined as 2 hours after the start of the meal.
Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) During Standardized Meal Test to Week 26: Core Period
Time frame · Baseline, Week 26
The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 26 value. Missing data was imputed using last observation carried forward (LOCF).
Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) During Standardized Meal Test to Week 52: Single Arm Extension Period
Time frame · Baseline, Week 52
The 2-hour PPG test measured blood glucose 2 hours after eating a liquid standardized breakfast meal. Change in PPG was calculated by subtracting baseline value from Week 52 value. Missing data was imputed using LOCF.
Change From Baseline in 2-Hour Blood Glucose Excursion During Standardized Meal Test to Week 26: Core Period
Time frame · Baseline, Week 26
2-hour plasma glucose excursion = 2-hour PPG value minus plasma glucose value obtained 30 minutes prior to the start of meal and before investigational medicinal product (IMP) administration if IMP was injected before breakfast. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 26 value. Missing data was imputed using LOCF.
Change From Baseline in 2-Hour Blood Glucose Excursion During Standardized Meal Test to Week 52: Single Arm Extension Period
Time frame · Baseline, Week 52
2-hour plasma glucose excursion = 2-hour PPG value minus plasma glucose value obtained 30 minutes prior to the start of meal and before IMP administration if IMP was injected before breakfast. Change in plasma glucose excursions were calculated by subtracting baseline value from Week 52 value. Missing data was imputed using LOCF.
Eligibility
Inclusion criteria : * Participants with type 2 diabetes mellitus diagnosed at least 1 year prior to screening visit. * Participants who were treated with one of the following GLP-1 receptor agonists for at least 4 months prior to screening visit 1 (V1), and with stable dose for at least 3 months prior to screening visit (V1): * Liraglutide (Victoza®) 1.8 milligram (mg) QD or 1.2 mg QD, if the 1.8 mg QD dose was not well tolerated according to the Investigator's judgment or * Exenatide (Byetta®) 10 microgram (µg) BID or of 5 µg BID, if 10 µg BID dose was not well tolerated according to the Investigator's judgment in combination with metformin (daily dose greater than equal to \[\>=\] 1500 mg/day or maximum tolerated dose \[MTD\]), with or without pioglitazone, with or without SGLT2 inhibitor, all at stable dose for at least 3 months prior to screening. or Participants who were treated with stable dose of one of the following GLP-1 receptor agonists for at least 6 months prior to screening visit (V1): * Exenatide extended-release (Bydureon®) 2 mg once weekly (QW), if well tolerated according to Investigator's judgment, * Albiglutide (Tanzeum®) 50 mg QW or 30 mg QW, if 50 mg QW was not well tolerated according to Investigator's judgment, * Dulaglutide (Trulicity®) 1.5 mg QW or 0.75 mg QW, if 1.5 mg QW was not well tolerated according to Investigator's judgment in combination with metformin (daily dose ≥1500 mg/day or MTD), with or without pioglitazone, with or without SGLT2 inhibitor, all at stable dose for at least 3 months prior to screening; -Signed written informed consent. Exclusion criteria: * At screening visit, age \<18. * Screening HbA1c \<7% and \>9%. * Pregnancy or lactation, women of childbearing potential with no effective contraceptive method. * Any use of antidiabetic drugs within 3 months prior to the screening visit other than those described in the inclusion criteria. * Previous treatment with insulin in the year prior to screening visit (note: short-term treatment with insulin \[\<=10 days\] due to intercurrent illness including gestational diabetes was allowed at the discretion of the study physician). * Laboratory findings at the time of screening, including: * Fasting plasma glucose (FPG) \>250 mg/dL (13.9 millimoles per litre \[mmol/L\]), * Amylase and/or lipase \>3 times the upper limit of the normal laboratory range (ULN), * Alanine transaminase or aspartate transaminase \>3 ULN, * Calcitonin \>=20 pg/mL (5.9 pmol/L), * Positive pregnancy test. * Participant who had renal function impairment with estimated glomerular filtration rate \<30mL/min/1.73m\^2 (using the Modification of Diet in Renal Disease formula) or end-stage renal disease. * Contraindication to use of insulin glargine, or lixisenatide or GLP-1 receptor agonist (Victoza®, Byetta®, Bydureon®, Tanzeum® or Trulicity®) according to local labeling. * Any contraindication to metformin or pioglitazone or SGLT2 inhibitor use, according to local labeling. * History of hypersensitivity to insulin glargine, or to any of the excipients. * History of allergic reaction to any GLP-1 receptor agonist or to meta-cresol. * Personal or immediate family history of medullary thyroid cancer (MTC) or genetic condition that predisposes to MTC (eg, multiple endocrine neoplasia type 2 syndromes). * History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy was already performed), chronic pancreatitis, pancreatitis during a previous treatment with incretin therapies, pancreatectomy. * Body mass index \<=20 or \>40 kg/m\^2. Exclusion criteria for the extension period: * Participants in the FRC arm with a rescue therapy and HbA1c \>8% at week 22. * Participants in the FRC arm who discontinued prematurely from FRC treatment before week 26. * Participants in the GLP-1 RA treatment arm after randomization. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study locations
Canada · Estonia · Germany · Israel · Italy · Romania · Slovakia · Spain · United States. Showing up to 24 locations stored in the fast local snapshot.
Investigational Site Number 8400064
Birmingham, Alabama, United States
Investigational Site Number 8400073
Fountain Hills, Arizona, United States
Investigational Site Number 8400047
Phoenix, Arizona, United States
Investigational Site Number 8400103
Bakersfield, California, United States
Investigational Site Number 8400137
Fresno, California, United States
Investigational Site Number 8400043
Huntington Park, California, United States
Investigational Site Number 8400124
Lamont, California, United States
Investigational Site Number 8400027
Lancaster, California, United States
Investigational Site Number 8400098
Los Angeles, California, United States
Investigational Site Number 8400013
Los Angeles, California, United States
Investigational Site Number 8400042
Mission Hills, California, United States
Investigational Site Number 8400006
Northridge, California, United States
Investigational Site Number 8400021
Orange, California, United States
Investigational Site Number 8400126
Rialto, California, United States
Investigational Site Number 8400094
Santa Ana, California, United States
Investigational Site Number 8400009
Ventura, California, United States
Investigational Site Number 8400071
Denver, Colorado, United States
Investigational Site Number 8400036
Denver, Colorado, United States
Investigational Site Number 8400114
Jacksonville, Florida, United States
Investigational Site Number 8400133
Miami, Florida, United States
Investigational Site Number 8400058
Port Charlotte, Florida, United States
Investigational Site Number 8400084
Tampa, Florida, United States
Investigational Site Number 8400112
West Palm Beach, Florida, United States
Investigational Site Number 8400045
Lawrenceville, Georgia, United States
Publications
Related trials
Sanofi · Type 2 Diabetes
Phase 4
Completed
105
2026-07
Shanghai Zhongshan Hospital · Type 2 Diabetes
Phase 4
Recruiting
1,316
2026-07
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
Sanofi · Type 2 Diabetes (T2D)
Phase 4
Recruiting
678
2026-03
Yanbing Li · Type 2 Diabetes
Phase 4
Not yet recruiting
324
2026-02
University Hospital, Toulouse · Parkinson Disease
Phase 2
Completed
156
2025-11
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
582
2025-09
Ohio State University · Cardiovascular Kidney Metabolic Syndrome
Not applicable
Active, not recruiting
23,280,000
2025-09
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.